Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
An article from
Dive Brief
Acquiring Vega Therapeutics, an offshoot of “hub-and-spoke” biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
Published June 8, 2026
An illustration of red blood cells.
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential - Incyte (NASDAQ:INCY
Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Incyte's Meury, now a buyer, sees $2B Vega deal as a step in blood treatments beyond Jakafi
Incyte compra Vega Therapeutics por até US$ 2 bi para expandir portfólio em hematologia
Novo underwhelmed by drug it once fought Pfizer for
Health Care Ticks Down Amid Deal Activity - Health Care Roundup
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying
Legend Biotech emerged as a rare market winner
